Probiotics in diarrhea: Myths and facts

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 2, Issue SUPPL. 3, 2010, Pages 23-28

  Qureshi, Absar A ^a   Omer, Shaista ^b   Eswar Kumar, K ^c   Bhajipale, N S ^a  

^a SGSPS Institute of Pharmacy   (India)

^b Soniya Education Trust's College of Pharmacy   (India)

^c ANDHRA UNIVERSITY   (India)

Author keywords

Diarrhea; Probiotics; Saccharomyces boulardii

Indexed keywords

ALPHA GLUCOSIDASE; AMINOPEPTIDASE; BACTERIAL TOXIN; BIOFLORIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; LACTASE; POLYPEPTIDE ANTIBIOTIC AGENT; PROBIOTIC AGENT; SPERMIDINE; SPERMINE; SUCRASE; UNCLASSIFIED DRUG;

ACUTE DIARRHEA; ANTIBODY PRODUCTION; ARTHRITIS; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL METABOLISM; BACTERIUM ADHERENCE; BIFIDOBACTERIUM BIFIDUM; BOVINE VIRAL DIARRHEA; CARBOHYDRATE METABOLISM; CECUM DISEASE; CHRONIC DIARRHEA; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENTERIC FEEDING; ENTEROCOCCUS FAECIUM; FUNGEMIA; GASTROINTESTINAL DISEASE; GROWTH INHIBITION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; INTESTINE FLORA; INTESTINE MUCOSA; INTESTINE SECRETION; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; MALABSORPTION; MEDICAL HISTORY; METABOLIC ACIDOSIS; MUCOSAL IMMUNITY; PROTEIN SECRETION; RECEPTOR BINDING; REVIEW; SACCHAROMYCES BOULARDII; SINGLE DRUG DOSE; STREPTOCOCCUS; STREPTOCOCCUS THERMOCEPHILUS; TRAVELLER DIARRHEA;

EID: 77957586514     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Long RL, Dipiro JT. Diarrhoea and constipation, Pharmacotherapy-A pathophysiological approach. 4th ed. Dipiro JT et al. Connecticut; Appleton and longs, 1999: 599606.
2. Van der Waaij D, Horstra H, Wiegersma N. Effect of p-lactam antibiotics on the resistance of the digestive tract of mice to colonization. J Infectious Diseases 1982; 146: 417-22.
3. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. J American Medical Association 1993; 289: 71-75.
4. Kabins SA. Outbreak of clindamycin-associated colitis. Annals of Internal Medicine 1975; 83: 830-31.
5. Mulligan ME, Citron D, Gabay E, Kirby B, George WL, Finegold SM. Alterations in human fecal flora, including in growth of Clostridium difficile, related to cefoxitin therapy. Antimicrobial Agents and Chemotherapy 1984; 26: 343-46.
6. Tedesco RJ, Barton RW, Alpers DH. Clindamycin-associated colitis. Annals of Internal Medicine 1974; 81: 429-33.
7. Bartlett JG. Antibiotic-associated diarrhea. Clinical infectious Diseases 1992; 15: 573-81.
8. Caetano JA, Parames MT, Babo MJ, Santos A, Ferreira AB, Freitas AA, et al. Immunopharmacological effects of Saccharomyces boulardii in healthy human volunteers. International J Immunopharmacol 1986; 8: 245-59.
9. McFarland LV, Mulligan ME, Kwok RYY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. New England J Med 1989; 320: 204-10.
10. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. Difficile-associated diarrhea in a cohort of hospitalized patients. J Infectious Diseases 1990; 162: 678-84.
11. Pierce PF, Wilson R, Silva J, Garagusi VF, Rifkin D, Fekety R, Nunez-Montiel O, Dowel VR, Hughes JM. Antibiotic associated pseudomembranous colitis: an epidemiological investigation of a cluster of cases. J Infectious Diseases 1982; 145: 169-74.
12. Aronsson B, Molby R, Nord CE. Anti-microbial agents and Clostridium difficile in acute enteric disease: apidemiological data from Sweden. J Infectious Diseases 1985; 151: 476-81.
13. Drapkin MS, Worthington MG, Chang TW, Razvi SA. Clostridium difficile colitis mimicking acute peritonitis. Archives of Surgery 1985; 120: 1321-22.
14. Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology 1984; 86: 174-93.
15. Goldin BR, Lichtenstein AH, Gorbach SL. Nutritional and metabolic roles of intestinal bacteria. In: Modern Nutrition in Health and Disease. Shils ME, Olson JA, Shike M (editors); Philadelphia USA: Lea and Febiger; 1994: 569-80.
16. Swords WE, Wu CC, Champlin FR, Buddington RK. Postnatal changes in selected bacterial groups of the pig colonic microflora. Biol Neonate 1993; 63: 191-200.
17. Zhang H, Malo C, Boyle CR, Buddington RK. Diet influences development of the pig (Sus scrofa) intestine during the first 76 hours after birth. J Nutr 1998; 128: 1302-10.
18. Midtvedt T. Microbial functional activities. In: Probiotics, Other Nutritional Factors and Intestinal Microflora. Nestle Nutrition Workshop Series Vol. 42. Hanson LA, Yolken RH (editors). Philadelphia, PA: Lippincott-Raven; 1999: 79-96.
19. Hagiage M. In: La flora intestionale-de lequilibre an desiquilibre. Vigol Maloine, Paris; 1994: 1-120.
20. Bernet JP, Marx J, Kempf H, Giard P, Walbanm O, Lacombe A, et al. Epidemiologic des diarrhees associees lanti biotherapic orale chez lnfant. In: Journi es Francophones de Pathologic Digestive; 1995.
21. Buts JP. The clinical significance of Clostridium difficile infections in infants and children. In: Rambaud JC, editor. Updates on Clostridium difficile. Springer-Verlag, Paris, 1996: 29-36.
22. Attwegg M. La Ebiotherapie E dans la diarrhee. Der Informierte Arzt; 1992: 13.
23. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 1996; 275: 870-76.
24. Fuller R. Probiotics in human medicine. Gut 1991; 32: 489-92.
25. McFarland LV, Elmer GW. Biotherapeutic agents past, present and future. Microecology Ther. 1995; 23: 46-73.
26. Messing B, Crenn P, Beua P, Boutron-Ruault MC, Rambaud JC, et al. Long-term survival and pa-renteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology 1999; 117: 1043-1050.
27. Periti P, Tonelli F. AttualitO bioterapeutiche degli agenti probiotici. Ruolo del Saccharomyces boulardii. Farm Ter 2000; XVII (1-2): 24-45.
28. Fuller R, Gibson GR. Modification of the intestinal microflora using probiotics and prebiotics. Gastroenterology 1997; 32 (Suppl 222): 28-31.
29. Goldin BR. Health benefits of probiotics. Br J Nutr 1998; 80 (Suppl 2): S203-S207.
30. Roberfroid MB. Prebiotics and synbiotics: concepts and nutritional properties. Br J Nutr 1998; 80 (Suppl 2): S197-S202.
31. Dunne C, Murphy L, Flynn S et al. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trails. Antonie Van Leeuwenhoek 1999; 76: 279-92.
32. Silva M, Jacobus NV, Deneke C, Gorbach SL. Antimicrobial substance from a human Lactobacillus strain. Antimicrob. Agents Chemother 1987; 31: 1231-233.
33. Vandenbergh PA. Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbial. Rev. 1993; 12: 221-38.
34. Ramare F, Nicoli J, Dabard J, et al. Trypsin-dependent production of an antimicrobial substance by a human Peptostreptococcus strain in gnotobiotic rats and in vitro. Appl. Environ. Microbiol. 1993; 59: 2876-883.
35. Kotz, CM, Peterson LR, Moody JA, Savaiano DA, Levitt MD. Effect of yoghurt on Clindamycin-induced Clostridium difficile colitis in hamsters. Digest. Dis. Sci 37, 1992; 37: 129-32.
36. Blomberg L, Henmiksson A, Conway PL. Inhibition of adhesion of Escherichia coli K88 to piglet ileal mucus by Lactobacillus spp. Appl. Environ. Microb. 1993; 59: 34-39.
37. Bernet MF, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophilus LA1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994; 34: 483-89.
38. Coconnier MH, Francoise B, Chauvefre G, Servin AL. Adhering heat-killed human Lactobacillus acidophilus. Strain LB inhibits the process of pathogenicity of diarrhoeagenic bacteria in cultured human intestinal cells. J Diarrhoeal Dis. Res. 1993; 11: 235-42.
39. Rigothier MC, Maccario J, Gayral P. (Inhibitory activity of Saccharomyces yeasts on the adhesion of Entamoeba histolytica trophozoites to human erythrocytes in vitro. Parasitol. Res. 1994; 80: 10-15.
40. Ducluzeau R, Bensaada M. Effect compare de I'administration unique ou en continu du Saccharomyces boulardii sur I'etablissement de diverses souches de Candida dans le tractus digestif de souris gnotoxeniques. Annales de Microbiologie (Paris) 1982; 133: 491-501.
41. Vidon N, Huchet B, Rambaud JC. Influence de Saccharomyces boulardii sur la secretion jejunale induite chez le rat par la toxin cholerique. Gastroenterologie clinique et Biologie 1986; 10: 13-16.
42. Delmee M, Buts JP. Clostridium difficile-associated diarrhoea in children. In: Management of Digestive and Liver Disorders in infants and Children. Textbook JP Buts and E Sokal eds, Elsevier Sciences, Amsterdam 1993: 371-79.
43. Buts JP, Corthier G, Delmfe M. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. Journal of Ped. Gastroenterol. And Nutr. 1993; 16: 419-25.
44. Buts JP, Weber AM. Roy CC. Morin CL. Pseudomembranous enterocolitis in childhood. Gastroenterology 1977; 73: 823-27.
45. Onderdonck AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing Clostridia. N. Engl. J. Med. 1978; 298: 531-34.
46. Corthier G, Dubos F, Ducluzeau R. Prevention of Clostridium difficile induced mortality in gnotobiotic mice by Saccharomyces boulardii. Canadian Journal of Microbiology 1986; 32: 894-96.
47. Massot J, Sanchez O, Couchy R, Astoin J, Parodi AL. Bakteriopharma-kologische aktivitt von Saccharomyces boulardii bei der Clindamycin-induzierten kolitis in hamster. Arzeimittel Forshung 794-97.
48. Castex F, Corthier G, Jouvert S, Elmer GW, Guibal J, Lucas F, Bastide M. Prevention of experimental pseudomembranous cecitis by Saccharomyces boulardii: topographical histology of the mucosa, bacterial counts and analysis of toxin production. In: Dougherty SJ, Hentges DL, Lyerly DM et al. (eds). Microecology and Therapy, Vol 19. Institute for Microbiology Herborn-Hill, 1989: 241.
49. Corthier G, Lucas R, Jouvert S, Castex F. Effect of Saccharomyces boulardii treatment on the activity of Clostridium difficile toxin in mouse digestive tract. Toxicon 1992; 30: 1583-1589.
50. Marteau P, Rambaud JC. Potential of using lactic acid bacteria for therapy and immuno-modulation in man. FEMS Microbiology Reviews 1993; 12: 207-20.
51. Kaila M, Isolauri E, Saxelin M, Arvilommi H, Vesikari T. Viable versus inactivated lactobacillus strain GG in acute rotavirus diarrhoea. Archives of Disease in Childhood 1995; 72: 51-53.
52. Buts JP, Bernasconi P, Vaerman JP, and Dive C. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Digestive Diseases and Sciences 1990; 35: 251-56.
53. Buts JP, De Keyser N, Kolanowski J, Sokal E, Van Hoof F. Maturation of villus and crypt cell functions in rat small intestine role of dietary polyamines. Digestive Diseases and Sciences 1993; 38: 1091-1098.
54. Tutton PJM, Barkla DH. Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells (review). Anticancer Research 1987; 7: 1-12.
55. buts JP, Bernasconi P, Van Craynest MP, Maldague P, De Meyer R. Response of human and rat intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatric Research 1986; 20: 192-96.
56. Buts JP, De KeyserN, De Raedemaeker L. Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatric Research 1994; 36: 552-527.
57. Clements ML, Levine MM, Black RE, Robins-Browne Luis A. Cisneros RM, Drusano GL, et al. Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli. Antimicrobial agents and chemotherapy 1981; 20: 104-108.
58. Pozo-Olano JD, Warram JH, Gomez RG, Cavazos MG. Effect of a Lactobacilli preparation on traveler's diarrhea. Gastroenterology 1978; 74: 829-30.
59. Heimburger DC, Sockwell DG, Geels WJ. Diarrhea with enteral feeding: Prospective reappraisal of putative causes. Nutrition 1994; 10: 392-96.
60. Kollaritsch HH, Kemsner P, Wiedermann G, Scheiner O. Prevention of traveler's diarrhoea; comparision of different non-antibiotic preparations. Travel Medicine International 1989: 9-17.
61. Katelaris PH, Salam I, Farthing MJG. Lactobacilli to prevent traveler's diarrhea? The New England Journal of Medicine 1995; 333: 1360-361.
62. Boulloche J, Mouterde O, Mallet E. Traitement des diarrhees aigues chez le nourisson et le jenue enfant. Annales de Pediatrtie 1994; 41: 457-63.
63. Oksanen PJ, Salminen S, Saxelin M, Hamalainen P, Ihantola-Vormisto A, Muurasiemi-Isoviita L, et al. Prevention of Traveller's Diarrhoea by Lactobacillus GG. Annals of Medicine 1990; 22: 53-56.
64. Wunderlich PF, Braun L, Fumagalli I, D'Apuzzo V, Heim F, Karly M, et al. Double blind report on the efficacy of lactic acid-producing enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. The J of Internal Medical Research 1989; 17: 333-38.
65. Mitra AK, Rabbani GH. A Double-Blind, Controlled trail of bioflorin (Streptococcus faecium SF68) in adults with acute diarrhea due to vibrio cholerae and enterotoxigenic escherichia coli. Gastroenterology 1990; 99: 1149-152.
66. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhea and shedding of rotavirus. Lancet 1994; 344: 1046-1049.
67. Adam et al. Essais cliniques controle en double insu de I'ultra-levure lyophilisee (etude multicentrique par 25 medecins de 388 cas). M.C.D. 1976; 5: 401-406.
68. Tempr JD, Steidel AL, Blehaut H, Hasselman M, Lutun Ph, Maurier F. Prevention par Saccharomyces boulardii des diarrhees de I'alimentation enterale debit continu. La Semaine des Hopitaux de Paris 1983;l 59: 1409-412.
69. Schlotterer M, Bernasconi P, Lebreton F, Wasserman D. Intert de Saccharomyces boulardii dans la tolerance digestive de la nutrition enterale debit continu chez le. Nutr. Clin. Metabol. 1987; 1: 31-34.
70. McFarland LV, Surawicz CM, Greenberg RN, Feketey R, Elmer GW, Moyer KA, et al. A randomized placebo-controlled trail of Saccharomyces boulardii in combination with standard antibiotics for clostridium difficile disease. The J American Medical Association 1994; 271: 1913-918.
71. Cetina-Sauri G, Sierra Basto G. Evaluation therapeutique de Saccharomyces boulardii chez des enfants souffrant de diarrhee aigu. Annales de Pediatrie 1994; 41: 397-400.
72. Gechter W, Chase D, Hagenhoff G. Saccharomyces boulardii in acute adult diarrhea. Ml nch. Med. Wschr. 1990; 132: 188-92.
73. Castanada C. Effects of Saccharomyces boulardii in children with chronic diarrhea, especially due to giardiasis. Revista mexicana de puericultura y pediatria 1995: 2.
74. Saint-Marc T, Blehaut H, Musial Ch, Touraine JL. Diarrhen im zusammenhang mit AIDS Doppelblindstudie mit Saccharomyces boulardii Sem. HOp. Paris 1995; 71: 735-41.
75. Coronada BE. Antibiotic-Induced D-Lactic Acidosis. Ann Itern Med 1995; 122: 839-42.
76. Susman JI, Baron EJ, Golberg SM, Kaplan MH, Pizzarello RA. Clinical manifestations and therapy of lactobacillus endocarditis: Report of a case and review of the literature. Reviews of Infectious Diseases 1986; 8: 771-76.
77. Rahman M, Chest infection caused by Lactobacillus casei ss rhamnosus. Britisch Medical Journal 1982; 284: 471-72.
78. Millis JA. Do bacteria cause chronic polyarthritis. The New England Journal of Medicine 1989; 230: 245-256.
79. Steward-Tull DES. The immunological activities of bacterial peptidoglycans. Ann. Rev. Microbiol. 1980; 34: 311-40.
80. McFarland LV, Bernasconi P. Saccharomyces boulardii: A review of an innovative biotherapeutic agent. Microbial Ecology in Health and Disease 1993; 3: 201-5
81. Berg R, Bernasconi P, Flower D, Gautreux M. Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. The J Infectious Diseases 1993; 168: 1314-318.
82. Elmer G, Moyer K, Vega R, Surawicz C, Collier A, Hooton M, McFarland L. Pharmacokinetic studies of Saccharomyces boulardii in patients with HIV related chronic diarrhea in healthy volunteers. XIX International Congress on Microbial Ecology and Disease. Rome, September 1994: 18-21 (abstract book).
83. Saint-Marc T, Rossello-Prats L, Touraine JL. Effecacite de Saccharomyces boulardii dans le traitement des diarrhees du SIDA. Annales de Medicine Interne (Paris) 1991; 142: 64-65.
84. Adams MR, Marteau P. On the safety of lactic acid bacteria from food. Int J Food Microbiol 1995; 27: 263-64.
85. Bozzetti F, Gavazzi C, Cozzaglio L, et al. Perioperative TPN m malnourished patients with gastrointestinal cancer: a randomized clinical trail. Clin Nutr 1997; 16(2): 10.
86. McFarland LV, Bernasconi P. Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microbial Ecology Health Dis 1993; 6: 157-71.
87. Surawicz CM, McFarland LV. Risks of biotherapeutic agents. In: Biotherapeutic agents and infectious diseases (Elmer GW, McFarland LV, Surawics CM, Eds), Humana Press Inc, Totowa, NJ 1999b; 12: 263-268.
88. Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000; 19: 16-20.
89. Oberholzer c, Oberholzer A, Clare-Salzler M, Moklawer LL. Apoptosis in sepsis: a new target for therapeutic exploration. FASEB J 2001; 15: 879-892.
90. Rowlands BJ, Gardiner KR. Nutritional modulation of gut inflammation. Proc Nutr Soceity 1998; 57: 395-401.
91. Blum S, Alvarez S, Haller D, Perez P, Schiff Tin EJ. Intestinal microflora and the interaction with immunocompetetn cells. Anotonie van Leeuwenhoek 1999; 76: 199-205.
92. Roffe C. Biotherapy for Antibiotic associated and other Diarrhea, J of Infection 1996;32: 1-10.
93. Lupke NP. Teichman A. Diarrhoea, Die positieve Liste 1996.
94. WHO. Saccharomyces boulardii: a valuable adjunct in recurrent Clostridium difficile disease? WHO Drug Information 1995; 9: 15-16.